Abstract:
Embodiments of the invention generally provide a method and apparatus for bridging session initiation protocol and universal plug and play devices. One embodiment of the invention specifies a method that enables legacy session initiation protocol and universal plug and play devices to communicate with each other (i.e., to access services), where the term “legacy” is defined to mean IETF RFC 3261-compliant for session initiation protocol devices, and DLNA 1.0-compliant for universal plug and play devices. The method enables inter-working between the session initiation protocol and universal plug and play devices without requiring changes to the legacy devices. One embodiment of the invention is a transparent software bridge that enables these features.
Abstract:
A network device may receive a request from a local device to establish a connection with a another device. The request may include an internal network identifier of the local device. The network device may evaluate a plurality of external network identifiers, associated with the network device based on selected criteria. The network device may also, or alternatively, evaluate the external network identifiers by identifying an external network identifier that is already mapped to, or paired with, the internal network identifier. The network device may select an external network identifier, of the plurality of external network identifiers, based on the evaluation and establish the connection requested by the local device using the internal network identifier and the external network identifier.
Abstract:
The invention describes process for demetallation of vegetable oils and animal fats to reduce metal content below 1 ppm to make them suitable for hydroprocessing feedstocks. The process comprises acid treatment with very low concentration of acids, utilizing synergistic effect of phosphoric acid and citric acid, followed by counter-current treatment with clay without intermediate step of water washing and treatment with ion exchange resin.
Abstract:
The present invention provides Immunosuppressive compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signalling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides pharmaceutical compositions comprising the Immunosuppressive peptide compounds or modified peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.
Abstract:
Disclosed are novel compounds which are useful as therapeutics, especially in anti-neoplastic therapy and in other therapeutic regimes where cysteine protease inhibition is implicated.
Abstract:
Techniques are described for facilitating access of computing system users to restricted functionality, such as internal functionality of a business or other organization (e.g., internal systems and/or confidential information available to some or all business employees or other organization members). The restricted functionality access may in some situations be provided in conjunction with publicly available information from the organization, such as to use that publicly available information as part of a user interface that allows an authorized subset of users to access the restricted functionality. In some situations, the restricted functionality access may be facilitated by an access provider system that executes on a client computing system of an authorized user, such as a program operating in conjunction with another presentation program that presents publicly available information (e.g., as an extension program for the presentation program), and that modifies the interactions available to the user when using the presentation program.
Abstract:
A method for a messaging engine to control messaging within a virtual machine having a heap is disclosed. The messaging engine creates a list of destinations associated with a messaging engine and receives parameters associated with the heap. The messaging engine determines total heap usage and based on the parameters associated with the heap and the total heap usage, controls message production rates of producers associated with the destinations.
Abstract:
A method and system for managing inventory by expected profitability. In one embodiment, a method may include individually evaluating a respective expected profitability for each of a number of inventory items, and individually determining a disposition of each of the number of items dependent upon its respective expected profitability. In one particular implementation of the method, individually evaluating the respective expected profitability of a given item may include forecasting an estimated date of transaction corresponding to the given item, forecasting an estimated revenue corresponding to the given item as of the estimated date of transaction, estimating accrued costs of holding the given item until the estimated date of transaction, and comparing a total cost of the given item against the estimated revenue, where the total cost may include the accrued costs of holding the given item until the estimated date of transaction.
Abstract:
A semiconductor device is disclosed including an electromagnetic radiation shield. The device may include a substrate having a shield ring defined in a conductance pattern on a surface of the substrate. One or more semiconductor die may be affixed and electrically coupled to the substrate. The one or more semiconductor die may then be encapsulated in molding compound. Thereafter, a metal may be plated around the molding compound and onto the shield ring to form an EMI/RFI shield for the device.
Abstract:
Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.